15 June 2022, 4:15pm – 5:15pm PDT at the BIO International Convention
Join our SVP Drug Discovery, Colin Stubberfield, at BIO 2022 for a panel discussion titled Tackling Post-Covid Cognitive Impairment. Find out from Dr Stubberfield how our combinatorial analysis of COVID-19 is identifying common pathophysiologies across multiple diseases including ME/CFS, Parkinson’s, and Alzheimer’s, which are all leading to cognitive decline.
Colin will be joined by Kiri Granger, Chief Scientific Officer at Cambridge UK-based Monument Therapeutics; Travis Bond, CEO at Washington-based digital health company Altoida, Paula Moran, Scientific consultant in Psychopharmacology and honorary Associate Professor at the University of Nottingham.
Widespread evidence shows that cognitive problems are the second most commonly reported symptom (after fatigue) in the >20% of individuals globally suffering from post-COVID syndrome. 86% of people reporting memory problems said that this impacts their ability to work.
Several mechanisms have linked COVID-19 infection with cognitive impairment, but a growing body of research has demonstrated similarities in the pathology of post-COVID cognitive changes such as neuroinflammation and other brain conditions, including Alzheimer’s disease, ‘chemo brain’ and other post-viral syndromes following infections such as influenza, HIV or Ebola.
There is now an urgent need to develop both diagnostic and treatment options for post-COVID cognitive impairment. In the UK, the NHS alone has recently invested £100 million to support long-COVID services and to establish pediatric hubs to co-ordinate care for young people.
Moderator:
Dr. David Cox, Health Journalist
Speakers:
- Colin Stubberfield, SVP Drug Discovery, PrecisionLife
- Kiri Granger, Chief Scientific Officer, Monument Therapeutics
- Paula Moran, Associate Professor, University of Nottingham
- Travis Bond, Chief Executive Officer, Altoida
Attending BIO 2022?
Our SVP Drug Discovery, Dr Colin Stubberfield, and SVP Healthcare, Simon Beaulah, will be meeting potential partners at BIO in San Diego, CA from 13-16 June.
PrecisionLife has novel drug targets with genetic linkage and patient stratification biomarkers in multiple chronic diseases. We also have a pipeline of indication extension opportunities at all stages of development, with all assets available for partnering.
Click below to send PrecisionLife a meeting request in the BIO partnering system.
